The High-Stakes Battle for Cancer's Next Frontier: SOTIO's Patent Victory

PRAGUE, Czech Republic – July 21, 2026 – In the high-stakes world of cancer therapy development, intellectual property battles are often as fierce as the diseases they aim to conquer. Today, SOTIO Biotech, a clinical-stage company backed by the formidable PPF Group, secured a crucial victory in this arena. The Boards of Appeal of the European Patent Office (EPO) unequivocally upheld a key patent for SOT201, the company's next-generation cancer immunotherapy. The decision not only solidifies SOTIO's commercial footing in Europe but also casts a bright spotlight on a promising new class of drugs designed to outsmart cancer's most stubborn defenses.

The patent, EP 3 444 271 B1, was challenged by pharmaceutical giant Sanofi, a move that underscores the perceived value of the underlying technology. This legal skirmish is more than just corporate maneuvering; it's a proxy war for the future of immuno-oncology, a field desperate for breakthroughs for patients who have exhausted all other options.

A Two-Pronged Attack on Cancer

At the heart of this story is SOT201, a molecule known as an immunocytokine. It represents a sophisticated evolution of the checkpoint inhibitors that have revolutionized cancer treatment over the past decade. While drugs like Keytruda and Opdivo work by releasing the brakes on the immune system (blocking proteins like PD-1), SOT201 does that and more. It’s a dual-action agent designed to both release the brakes and slam the accelerator on the body's most effective cancer-killing cells.

SOT201 fuses a PD-1 targeting antibody with a specially engineered form of Interleukin-15 (IL-15), a potent cytokine that stimulates the proliferation and activation of T-cells and Natural Killer (NK) cells. The key innovation, covered by the now-validated patent, is the conjugation of IL-15 with the “sushi domain” of its receptor. This unique structure was found to be critical for maintaining the cytokine's powerful biological activity when fused to an antibody, a significant hurdle that had stymied earlier designs.

Critically, SOT201 is engineered for “cis-activation,” meaning it is designed to preferentially activate the immune cells that it binds to via the PD-1 receptor—specifically, the PD-1 positive CD8+ T-cells often found exhausted and ineffective within a tumor. This targeted approach aims to concentrate the powerful immune-stimulating effects of IL-15 directly where they are needed most, potentially avoiding the severe systemic toxicities that have plagued less targeted cytokine therapies. By simultaneously blocking the PD-1 “off” signal and delivering a powerful IL-15 “on” signal to the same cell, SOT201 has the potential to reinvigorate a patient’s anti-tumor response, even in cancers that have become resistant to standard checkpoint inhibitors.

A Legal Fortress in a Competitive Battlefield

The EPO Boards of Appeal's decision to uphold the patent as granted is a major strategic win. It confirms the novelty and ingenuity of the invention co-owned by SOTIO's affiliate Cytune Pharma and its French academic partners, AP-HP and INSERM. For a clinical-stage company, a fortified patent portfolio is a critical asset, serving as a shield against competitors and a beacon for potential partners and investors.

"We are pleased that the Boards of Appeal have upheld this important patent," said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO, in a statement. "The decision validates the strength of the underlying invention and reinforces the intellectual property supporting SOT201." Spisek rightly connected the legal victory to the clinical progress, adding that the milestone comes as the program generates "encouraging clinical data, including objective responses in heavily pre-treated patients."

This is the crux of the matter. The patent provides the commercial protection needed to justify the enormous cost and risk of late-stage clinical development. The ongoing Phase 1 VICTORIA-01 study is currently evaluating SOT201 in patients with advanced solid tumors who have few, if any, remaining treatment options. Early reports of objective responses and a high disease control rate in this heavily pre-treated population are precisely the signals the oncology world looks for in a potential game-changer.

The Shadow of Big Pharma

That a heavyweight like Sanofi, alongside the more obscurely named Strawman Limited, would invest the time and resources to challenge SOTIO's patent speaks volumes. In the pharmaceutical industry, patent opposition is a form of competitive intelligence and strategic maneuvering. It can be a tactic to clear a path for one's own competing product, to gain leverage in future licensing negotiations, or simply to test the strength of a competitor's intellectual property fortress.

Regardless of the specific motive, Sanofi's failed challenge is an implicit acknowledgment of the potential threat—and promise—of SOT201's technology. The immuno-oncology market is fiercely contested, and control over novel mechanisms like PD-1-targeted IL-15 delivery is a prized possession. For SOTIO, successfully defending its patent against one of the world's largest pharmaceutical companies is a resounding validation. It proves their innovation is not only scientifically sound but legally robust, a crucial distinction in a field where billions of dollars are at stake.

SOTIO's Broader Ambition

This patent victory does not exist in a vacuum. It bolsters a single, albeit important, program within SOTIO's broader and ambitious pipeline. The company is aggressively pursuing next-generation antibody-drug conjugates (ADCs) like SOT109 and SOT106, which recently received Fast Track and Orphan Drug designations from the FDA, respectively. This diversified strategy, focusing on multiple advanced therapeutic platforms, is made possible by the substantial financial backing of its owner, PPF Group, an international investment firm.

This stability allows SOTIO to think long-term and pursue high-risk, high-reward science. While the legal battle for SOT201 may be won, the ultimate test will take place in the clinic. The full data from the VICTORIA-01 trial and subsequent studies will determine if the elegant science of this dual-action immunocytokine can translate into meaningful, durable benefits for patients with advanced cancer. The EPO's decision ensures that if SOT201 does succeed, SOTIO will be in the driver's seat to bring this innovation to the patients who need it most.